Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection

Among pre- and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), combinations of an aromatase inhibitor (AI) or fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) have demonstrated improved progression-free survival (PFS) and overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Parati, Maria Chiara, Pedersini, Rebecca, Perego, Gianluca, Reduzzi, Roberto, Savio, Tommaso, Cabiddu, Mary, Borgonovo, Karen, Ghilardi, Mara, Luciani, Andrea, Petrelli, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013420/
https://www.ncbi.nlm.nih.gov/pubmed/35440873
http://dx.doi.org/10.2147/BCTT.S341857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013420/
https://www.ncbi.nlm.nih.gov/pubmed/35440873
http://dx.doi.org/10.2147/BCTT.S341857

Ejemplares similares